Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 2154

Dr Sara A. Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Dr Sara A. Hurvitz talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from the MONALEESA-7 study into adding ribociclib to first-line endocrine therapy in pre-menopausal women with advanced breast cancer.

She explains that half of patients received placebo in addition to endocrine therapy and half received ribociclib.

Dr Hurvitz reports that at the 42 month landmark analysis 46% of patients in the placebo arm were still alive compared to 70% of patients who were in the ribociclib arm, a highly statistically significant improvement.

Read the news article here.

Watch the press conference here.

Watch a comment from Dr Burstein here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation